Department of Biomedical Sciences, College of Science, Cihan University-Erbil, Erbil, 44001, Kurdistan Region, Iraq.
Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Kurdistan Region, Erbil, Iraq.
Cell Commun Signal. 2024 Jun 14;22(1):329. doi: 10.1186/s12964-024-01713-8.
Respiratory disorders are among the conditions that affect the respiratory system. The healthcare sector faces challenges due to the emergence of drug resistance to prescribed medications for these illnesses. However, there is a technology called CRISPR/Cas9, which uses RNA to guide DNA targeting. This technology has revolutionized our ability to manipulate and visualize the genome, leading to advancements in research and treatment development. It can effectively reverse epigenetic alterations that contribute to drug resistance. Some studies focused on health have shown that targeting genes using CRISPR/Cas9 can be challenging when it comes to reducing drug resistance in patients with respiratory disorders. Nevertheless, it is important to acknowledge the limitations of this technology, such as off-target effects, immune system reactions to Cas9, and challenges associated with delivery methods. Despite these limitations, this review aims to provide knowledge about CRISPR/Cas9 genome editing tools and explore how they can help overcome resistance in patients with respiratory disorders. Additionally, this study discusses concerns related to applications of CRISPR and provides an overview of successful clinical trial studies.
呼吸系统疾病是影响呼吸系统的疾病之一。由于这些疾病的处方药物出现耐药性，医疗保健部门面临挑战。但是，有一种名为 CRISPR/Cas9 的技术，它使用 RNA 来引导 DNA 靶向。这项技术彻底改变了我们操纵和可视化基因组的能力，推动了研究和治疗开发的进步。它可以有效地逆转导致耐药性的表观遗传改变。一些关注健康的研究表明，在使用 CRISPR/Cas9 靶向基因时，对于减少呼吸系统疾病患者的耐药性具有挑战性。然而，必须认识到这项技术的局限性，例如脱靶效应、Cas9 对免疫系统的反应以及与递送方法相关的挑战。尽管存在这些局限性，本综述旨在提供有关 CRISPR/Cas9 基因组编辑工具的知识，并探讨它们如何帮助克服呼吸系统疾病患者的耐药性。此外，本研究还讨论了与 CRISPR 应用相关的问题，并概述了成功的临床试验研究。
